Cardiovascular disease (CVD) is the leading cause of mortality and morbidity worldwide, with four out of five CVD deaths being due to myocardial infarction or stroke. Despite many initiatives that have been established for CVD prevention and risk management, and new therapies to treat existing CVD, patients continue to die from cardiac events.

Advances in biomarker research and developments related to CVD have led to more sensitive screening methods, a greater emphasis on its early detection and diagnosis, and improved treatments resulting in more favorable clinical outcomes. Presently, the use of biomarkers for different purposes in CVD remains an important area of research and several new developments are still underway.

The aim of this Special Issue is to bring together original research and review articles that discuss the latest updates on prognostic, pharmacodynamic, and predictive biomarkers of cardiovascular disease, focusing on methods to evaluate their incremental yield, including clinical utility. Special emphasis will also be given to novel heart failure biomarkers in current practice and the impact of post-mortem cardiac markers and their applicability.

Potential topics include but are not limited to the following:

• Biomarkers in myocardial infarction
• Biomarkers in myocardial fibrosis
• Biomarkers in hypertension
• Post-mortem cardiac markers
• Post-mortem biochemistry of myocardial biomarkers